Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation
PEPTAVO
The Stack Source LLC1908 E 11th Street Austin, TX 78702support@peptavo.com(512) 827-8158DBA: Peptavo
Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation
Get volume discounts if you are getting 3 or more clinicians certified
Book a Call
To add peptide therapy to your practice legally, prescribe only within your license, source every compound from a licensed pharmacy that may lawfully make it, and document consent and monitoring for each patient. Here is the full checklist: training, scope, sourcing, insurance, consent, charts, pricing, and marketing.
To add peptide therapy to your practice legally, you need three things in place before the first prescription: authority to prescribe under your own license and state rules, a licensed pharmacy that may lawfully compound or supply each peptide you plan to use, and a written process for consent, monitoring, and documentation. Everything else, from pricing to marketing, is built on top of those three.
This guide walks through each step in the order a practice usually meets them. It is written for physicians, nurse practitioners, and physician assistants adding peptides to an existing practice or starting a peptide therapy clinic, and it links to our deeper guides wherever a step needs more than a few paragraphs.
Checked October 15, 2026. Peptavo trains clinicians to prescribe peptides and sells no peptides. This is educational content, not legal advice. Have a healthcare attorney in your state review your plan, your consent forms, and your business structure before you launch.
| Step | What to have in place | Where it can go wrong |
|---|---|---|
| 1. Training | Accredited education in the compounds, dosing, contraindications, and monitoring | Prescribing from vendor protocols or patient requests |
| 2. Scope and licensure | Prescriptive authority in every state where your patients are | NP or PA agreements that don't cover the service; telehealth across state lines |
| 3. Compound status | Each peptide checked against FDA's current compounding lists | Relying on a pharmacy flyer or last year's status |
| 4. Sourcing | One or more licensed 503A pharmacies, or a 503B facility for office stock | Research use only vials; a pharmacy that can't ship to your patient's state |
| 5. Malpractice | Written confirmation that peptide therapy is covered | Assuming an existing policy covers off-label compounded drugs |
| 6. Business structure | Ownership, dispensing, and fee arrangements reviewed by counsel | Lay ownership in a corporate practice state; undisclosed markups |
| 7. Consent and intake | A peptide-specific consent and a contraindication screen | Generic consent that never mentions compounding or evidence limits |
| 8. Documentation and monitoring | Problem list, rationale, prescription detail, labs, and follow-up | Refills without a visit; no record of the pharmacy used |
| 9. Pricing | Itemized, cash-pay fees for consults, monitoring, and compounds | Folding a large markup into one program fee |
| 10. Marketing | Claims limited to what you can substantiate | Disease and anti-aging claims about unapproved compounds |
No license comes with peptide training. Most physicians, NPs, and PAs met the GLP-1 drugs in practice and never studied the compounded peptides at all, yet many of their new patients have been using peptides for years and will arrive with protocols copied from forums. Dr. Jesse Morse, who teaches Peptavo's course and runs a peptide practice in Miami, puts it bluntly: get comfortable before you start, because some patients will know more than an untrained prescriber.
Look for training that carries accredited continuing education credit, covers mechanisms, dosing, contraindications, and monitoring for each compound so you can build your own protocols, and teaches the sourcing and documentation work in this guide. Our peptide certification cost guide compares the accredited programs on price and credit.
Peptides that are prescription drugs are prescribed under the same authority as any other prescription drug. Physicians can prescribe them in every state. Nurse practitioners and physician assistants can too, but what each needs varies by state: some NPs practice independently, others need a collaborative or supervisory agreement, and a PA's agreement may have to name the service. Our who can prescribe peptides guide has a sourced 50-state table of NP practice authority.
Two scope questions catch practices most often. The first is delegation: who in your practice may give an injection, teach a patient to self-inject, or answer dosing questions, and under whose order. The second is telehealth. You must be licensed in the state where the patient is located at the time of the visit, and each state sets its own rules for establishing a patient relationship remotely. A peptide that is also a controlled substance, such as testosterone, adds federal telemedicine prescribing rules on top. State rules layer on top of all of this, and our US legality guide and its California and Texas spokes cover the details.
"Peptides" are not one legal category, and the status of individual compounds is still moving in 2026. Sort what you plan to offer into three groups.
FDA-approved peptide drugs. Semaglutide, tirzepatide, tesamorelin, bremelanotide, and the other approved peptide medicines can be prescribed like any approved drug, including off-label when you judge it appropriate for a patient. FDA regulates the drug, and your state board regulates how you practice medicine with it.
Compounded peptides. A 503A pharmacy may compound with a bulk substance only if it has a USP monograph, is a component of an approved drug, or is on the 503A Bulks List. Most peptides meet none of the three, so the practical question is FDA's interim category for each one. As of FDA's May 14, 2026 list, only a few peptides sit in Category 1, the category that gives a pharmacy a workable basis to compound. The twelve peptides FDA removed from Category 2 in April 2026, BPC-157 and TB-500 among them, moved to no category at all, and the advisory committee's July vote in favor of six of them is not law until FDA finalizes a rule. Our compounding categories guide shows where each peptide sits and how to check it yourself.
Research use only products. Vials sold online as "research use only" or "not for human consumption" have no lawful path to a patient. Never prescribe them, administer them, or direct a patient to them.
Because the lists change, the course treats checking each compound's current FDA status at the time you prescribe as part of the standard of care. Write down what you checked and the date.
For most peptide therapy, the source is a licensed 503A compounding pharmacy filling a prescription for a named patient. 503A product usually arrives as a premixed liquid that must ship overnight on ice. A 503B outsourcing facility makes larger batches, often as lyophilized powder that ships without a cold chain and is reconstituted with bacteriostatic water. Federal law generally lets a clinic keep office stock only from a 503B facility, because 503A compounding is tied to individual prescriptions.
Expect to need more than one pharmacy. Not every pharmacy ships to every state, none carries every compound, and cold shipping is the coordination burden practices underestimate most. Before you sign on with one, check its state licenses, its inspection history, and its accreditation, and ask for certificates of analysis that show potency, sterility, and endotoxin testing for the finished product. Our peptide compounding pharmacy guide is the full vetting checklist.
Many malpractice policies are silent on off-label prescribing of compounded drugs, and a silent policy leaves the question open until a claim tests it. Ask your carrier directly whether peptide therapy is covered, including compounded and off-label use and any in-office injections, and get the answer in writing. Dr. Morse's practice carries explicit coverage for peptides the same way it does for stem cell procedures. If your carrier excludes it, find one that does not before you see the first patient.
A practice that only adds a service line rarely needs a new entity, but three areas deserve an attorney's eye. Many states restrict who may own a medical practice or employ its clinicians, the corporate practice of medicine doctrine, which matters most for med spas and clinics with non-physician owners. Some states require a separate registration for physicians who dispense drugs from the office, or limit how much they may charge for it. And if any part of the practice bills Medicare, Medicaid, or another federal program, the Anti-Kickback Statute and the Stark Law apply to referral and pharmacy arrangements, with many states running their own versions for cash-pay care too.
Have counsel review your consent forms, patient agreements, and, for a telehealth practice, your terms of service and privacy policy. A template downloaded from another clinic was written for another state.
The intake is where a peptide practice says no. The single most important history question in the course is whether the patient has a personal history of cancer. Active or recent cancer, pregnancy, and breastfeeding are hard stops, and uncontrolled hypertension and cardiovascular disease call for caution and workup. Dr. Morse will not prescribe to a patient who refuses baseline labs, because the patient's risk then becomes his risk under his license.
Consent for peptide therapy covers more than a standard procedure consent. It should say that the product is compounded and not FDA-approved, describe how strong or weak the human evidence is for each compound, cover cost and the ongoing nature of treatment, name the predictable side effects, and record that the patient can manage injections on schedule. Our free peptide consent form has template language for each of these.
Off-label prescribing of compounded peptides carries medical-legal exposure that good documentation mostly answers. The record should show the assessment and contraindication screen, why you chose this protocol for this patient, the consent discussion, the goals you agreed on, and the prescription in full: compound, dose, route, timing, duration, and refills. Name the pharmacy in the chart. Record each follow-up with what you measured and what you changed, every adverse effect and how you handled it, and every time you declined or stopped treatment, with your reasoning.
Monitoring is part of the same record. Dr. Morse checks IGF-1 four to six weeks into a growth hormone secretagogue, repeats broader panels every three to six months, and allows no more than three refills before a paid follow-up visit. That rule keeps patients engaged and keeps prescriptions from running on without a clinician looking at the results.
Peptide therapy is almost entirely cash-pay, because insurers rarely cover compounded drugs. GLP-1 drugs prescribed for a covered use are the usual exception, which leaves many practices running a hybrid model. Decide between fee for service, a membership, and defined packages; the course notes that recurring structures fit the months of titration and monitoring that peptide protocols require, and that memberships bring steady income along with patients who call often.
Whatever model you choose, price consultations, monitoring, and compounds as separate lines. The practice both recommends and profits from the compounds, and an itemized bill is how you manage that conflict in the open. Our peptide therapy cost guide has current market ranges and what one physician charges.
Compounded peptides are not FDA-approved for any use, so claims that they treat, cure, or reverse a disease are where FDA and FTC enforcement starts. The FTC's 2022 Health Products Compliance Guidance expects health claims to rest on competent and reliable scientific evidence, which for most peptides does not exist at that level. Market what you can substantiate instead: your training, your sourcing, your lab-based protocols, and your monitoring. Leave out before-and-after promises, income claims, and urgency tactics. In a field full of overselling, the practice that tells patients the truth earns the referrals worth having.
Adding peptides to an established practice is the easier path. You already have a license, a malpractice carrier, an entity, patients, and staff, so the work is the ten steps above. Starting a standalone peptide therapy clinic adds the whole build: entity formation, corporate practice review if anyone other than a clinician will own it, a medical director arrangement where the state requires one, payment processing that accepts the category, and the patient acquisition that an existing practice gets from its own panel. Functional and integrative, sports and regenerative, longevity, aesthetic, and primary care practices each fold peptides in differently, and the course covers how each one does it.
Peptavo's accredited course covers the clinical side of this checklist compound by compound, and its tenth module is the practice side: intake, consent, monitoring, sourcing, documentation, telehealth, pricing, and ethical marketing, taught by Dr. Morse from his own practice. It costs $2,900 and carries 20 accredited credits for physicians, nurse practitioners, physician assistants, pharmacists, and more. Practices training more than one clinician can see group options on the peptide training for clinics page.
Yes. A licensed physician can prescribe peptide drugs in every state, under the same authority that covers any prescription drug. The real limits are sourcing, since many peptides have no lawful compounding pathway today, and the training to prescribe them safely.
No state requires a peptide-specific certification to prescribe. Your license is the legal authority. Training matters for safety, for your malpractice carrier, and for patients who ask how you learned, and accredited training also counts toward your continuing education requirements.
Yes, within their state's scope of practice. NPs with full practice authority can prescribe independently, while NPs in other states and PAs generally need a collaborative or supervisory agreement that covers the service. Check your state board's rules before you start.
Generally only when they come from a 503B outsourcing facility or are FDA-approved products. Federal law ties 503A compounding to prescriptions for individual patients, so a 503A pharmacy can't supply general office stock. Some states add their own limits.
Yes, if you are licensed in the state where the patient is, you follow that state's rules for establishing a patient relationship remotely, and your pharmacy can ship to the patient. Controlled substances such as testosterone carry additional federal rules for remote prescribing.
FDA-approved peptide drugs, and compounded peptides that a licensed pharmacy may lawfully make, which today means a short list in FDA's Category 1 or substances with another valid basis. BPC-157, TB-500, and the other peptides removed from Category 2 in April 2026 have no interim protection until FDA finalizes a rule.